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1. Introduction 
Tumorigenesis and metastasis are two processes with inter-related mechanisms. These 
include tumor growth and angiogenesis, detachment of tumor cells from the primary tumor, 
followed by migration through the local connective tissue and penetration into the 
circulation (intravasation). Once in the blood stream, tumor cells interact with circulating 
blood cells, arrest in the microvasculature of target organs, then extravasate and secondary 
proliferate. During each of these steps, integrin-mediated adhesion, migration, proliferation 
and survival of tumor cells and angiogenic endothelial cells play crucial roles [1,2]. 
Integrins are a family of heterodimeric transmembrane receptors that mediate cell-cell and 
cell-extracellular matrix (ECM) interactions. These cell adhesion molecules are composed by 
non covalent association of α and β subunits. Although 18 α and 8 β subunits have been 
described, only 24 different combinations have been identified to date [3]. Specific integrin 
heterodimers preferentially bind distinct ECM proteins. The repertory of integrins present 
on a given cell dictates the extent to which that cell will adhere to and migrate on different 
matrices. Several integrins, among others αv and α5β1, recognize the RGD sequence on 
their respective ligands. Other adhesive sequences in ECM proteins have also been 
observed, including the EILDV and REDV sequences that are recognized by integrin α4β1 in 
an alternatively spliced form of fibronectin [3]. On ligation to the ECM, integrins cluster in 
the plane of the membrane and recruit various signalling and adaptor proteins to form 
structures known as focal adhesions [4]. 
Integrin expression can also vary considerably between normal and tumor tissue. Most 
notably, integrins αvβ3, α5β1 and αvβ6 are usually expressed at low or undetectable levels 
in most adult epithelia but can be highly up-regulated in some tumors. Expression levels of 
some integrins, such as α2β1, decrease in tumor cells; potentially increasing tumor cell 
dissemination [5]. The integrin αvβ3 is particularly important for tumor growth and 
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invasiveness [6]. The receptor plays a major role in neo-vessels formation, its expression 
being strongly up-regulated in endothelial cells and specifically required during 
angiogenesis stimulated by basic fibroblast growth factor (bFGF) and tumor necrosis factor-
α [7,8]. αvβ3 is functionally involved in the malignant spread of various tumor cell types 
such as breast carcinoma, prostate carcinoma and melanoma, and supports tumor cell 
adhesion and migration through endothelium [9] and matrix proteins [10,1]. Blocking αvβ3 
is therefore expected to have a broad impact in cancer therapy and diagnosis. In the last 
decade, several clinical trials evaluating the efficacy of αvβ3 blockers have led to 
encouraging results. Thus, MEDI-522 (Vitaxin), a humanized antibody derived from the 
mouse LM609 monoclonal antibody, was recently reported to give positive results in a 
phase II trial enrolling patients with stage IV metastatic melanoma [11]. Cilengitide is an 
inhibitor of both αvβ3 and αvβ5 integrins; it is currently being tested in phase II trials in 
patients with lung and prostate cancers [12] and in phase II and Phase III trials studying 
their role against glioblastoma are currently underway.  
In addition to their role in tumor cells, integrins are also important for the host cellular 
response against cancer. Endothelial cells, fibroblasts, pericytes, bone marrow-derived cells, 
inflammatory cells and platelets all use integrins for various functions, including 
angiogenesis, desmoplasia and immune response. 
Nature has been a source of medicinal products for thousands of years among which snake 
venoms form a rich source of bioactive molecules such as peptides, proteins and enzymes 
with important pharmacological activities. International research and development in this 
area, based on multidisciplinary approaches including molecular screening, proteomics, 
genomics and pharmacological in vitro, ex vivo and in vivo assays, allow the identification 
and characterization of highly specific molecules from snake venom that can potently inhibit 
integrin functions. These anti-adhesive snake venom proteins belong to different families 
(phospholipases, disintegrins, C-type lectins and metalloproteinases). By targeting integrins, 
they exhibit various pharmacological activities such as anti-tumor, anti-angiogenic and/or 
pro-apoptotic effects. 
2. Snake venom protein families 
2.1. The Snake Venom Metalloproteinases (SVMP) 
Metalloproteinases are among the most abundant toxins in many Viperidae venoms. SVMPs 
are monozinc endopeptidases varying in size from 20 to 100 kDa. They are phylogenetically 
most closely related to the mammalian disintegrin and metalloproteinase (ADAM) family of 
proteins. SVMPs are grouped into several subclasses according to their domain organization 
[13, 14, 15]. P-I SVMPs are the simplest class of enzymes that contain only a metalloproteinase 
(M) domain. P-II SVMPs contain a M domain followed by a disintegrin (D) domain. P-III 
SVMPs contain M, disintegrin-like (D) and cysteine-rich (C) domains. Formally called P-IV, the 
heterotrimeric class of SVMPs that contain an additional snake C-type lectin-like (snaclec) 
domain [16] is now included in the P-III group as a subclass (P-IIId).  
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Most of the functional activities of SVMPs are associated with hemorrhage or the disruption 
of the hemostatic system, which are primarily mediated by the proteolytic activity of the M 
domain. SVMPs cause hemorrhage by disturbing the interactions between endothelial cells 
and the basement membrane through the degradation of endothelial cell membrane proteins 
(e.g., integrin, cadherin) and basement membrane components (e.g., fibronectin, laminin, 
nidogen, type IV collagen) [17]. Blood coagulation proteins (e.g., fibrinogen, factor X, 
prothrombin) are also targets of their proteolytic activities. 
Echis carinatus venom contains the specific prothrombin activators, ecarin [18,19] and 
carinactivase [20]. Adamalysin II, a non-hemorrhagic P-I SVMP isolated from Crotalus 
adamantus venom, cleaves and inactivates serum proteinase inhibitors including 
antithrombin III [21]. Kaouthiagin, isolated from the venom of Naja kaouthia specifically 
binds and cleaves von Willebrand factor (vWF), resulting in loss of both the ristocetin-
induced platelet aggregation and collagen-binding activity of vWF [22]. Additionally, a 
large number of the P-III SVMPs can inhibit platelet aggregation, thus enhancing the 
hemorrhagic state [23]. The hemorrhagic P-III SVMP jararhagin from the venom of Bothrops 
jararaca has been shown to degrade platelet collagen receptor α2β1 integrin in addition to 
fibrinogen and vWF, resulting in the inhibition of platelet aggregation [24]. Other platelet 
receptors are also degraded by SVMPs. GPIbα is cleaved by kistomin; mocarhagin and 
crotalin [25-27], and GPVI is degraded by alborhagin, crotarhagin and kistomin [28,29]. 
In the other side, it was reported that several SVMPs inhibited integrin-mediated adhesion 
of cancer cells on ECM proteins (table 1). BaG, a dimeric PIII class of SVMP from Bothrops 
alternatus with inactivated enzymatic domain but intact D/C domain, has been reported to 
inhibit fibronectin-mediated K562 cell adhesion via α5β1 integrin [30]. 
Proteins Snake Integrins Effects References 
VAP1, VAP2 Crotalus atrox α3,α6,β1 Induce apoptosis of HUVEC [31,36] 
HV1 Trimeruserus 
flavoviridis 
- 
Inhibits adhesion of HUVEC 
and induces apoptosis 
[32] 
Halysase Gloydius halys α1β1;α5β1 Inhibits proliferation and 
Induces apoptosis of HUVEC 
[33] 
VLAIPs Vipera lebetina
- 
Inhibits proliferation and 
Induces apoptosis of HUVEC 
[34] 
Graminelysin Trimeresurus 
gramineus 
α1β1;α5β1 Inhibits proliferation and 
Induces apoptosis of HUVEC 
[35] 
BaG Bothrops 
alternatus 
αβ Inhibits adhesion of K562 cells [30] 
TSV-DM Trimeresurus 
stejnegeri 
- 
Inhibits cell proliferation and 
induces transient cell 
morphologic changes of 
endothelial cells. 
[113] 
Table 1. SVMP affecting tumor cells 
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Several apoptosis-inducing proteins have been purified from hemorrhagic snake venom, 
such as VAP1 and VAP2 (Crotalus atrox), HV1 (Trimeresurus flavoviridis), halysase (Gloydius 
halys), and VLAIPs (Vipera lebetina) [31-34], graminelysin [35]. They are members of the 
SVMP and ADAM family and induce apoptosis of human umbilical vein endothelial cells 
(HUVECs) [31,36]. The detachment of endothelial cells and resulting apoptosis could be an 
additional mechanism for the disruption of normal hemostasis by SVMPs. TSV-DM a basic 
metalloproteinase from Trimeresurus stejnegeri venom inhibits cell proliferation and induces 
cell morphologic changes transiently of ECV304 cells. However, DNA fragmentation and 
DNA content analysis demonstrated that this metalloproteinase could not induce ECV304 
cells apoptosis. 
2.2. The disintegrins 
Disintegrins are a family of non-enzymatic and low molecular weight proteins derived from 
viper venom [37-39]. They are able to inhibit platelet aggregation and interact with adhesion 
molecules in particular integrins in a dose-dependent manner. They have a K / RTS 
sequence which is known as the RGD adhesive loop [37-39]. Their primary structure shows 
a strong conservation in the arrangement of cysteines [38]. Most disintegrins represent the 
C-terminal domain of metalloproteinases PIIa, d and e classes and are released into the 
venom by proteolytic cleavage [40,37,38]. A minority of these proteins exist as D / C 
domains from the class of SVMPs PIIIb.  
Disintegrins can be conveniently divided into five different groups according to their length 
and the number of disulfide bridges [41]. The first group includes short disintegrins, single 
polypeptide composed of 49 - 51 amino acids with four disulfide bridges. The second group 
comprises medium disintegrins containing about 70 amino acids and six disulfide bridges. 
The third group includes long disintegrins of 83 residues linked by seven disulfide bridges. 
The disintegrin domains of PIII snake-venom metalloproteinases, containing approx. 
hundred amino acids with 16 Cysteine residues involved in the formation of eight disulfide 
bonds, constitute the fourth subgroup of the disintegrin family. Unlike short-, medium- and 
long-sized disintegrins, which are single-chain molecules, the fifth subgroup is composed of 
homo and heterodimers. The dimeric disintegrins subunits contain about 67 residues with 
four disulfide intra-chain bridges and two interchain bridges [42,43].  
Although disintegrins are highly homologous, significant differences exist in their affinity 
and selectivity for integrins, which explains the multitude of effects of these molecules 
(Table 2). 
Disintegrins were first identified as inhibitors of platelet aggregation and were subsequently 
shown to antagonize fibrinogen binding to platelet integrin αIIbβ3 [44,45]. After that, 
studies on disintegrins have revealed new uses in the diagnosis of cardiovascular diseases 
and the design of therapeutic agents in arterial thrombosis, osteoporosis, and angiogenesis-
related tumor growth and metastasis (table 2). Triflavin from Trimeresurus flavoviridis venom 
was one of the first RGD-disintegrins shown to inhibit angiogenesis both in vitro and in vivo 
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[46]. Triflavin strongly inhibited cell migration toward vitronectin and fibronectin nearly 
thirty orders of magnitude greater than anti-αvβ3 monoclonal antibodies [46]. Triflavin was 
also more effective in inhibiting TNF-α-induced angiogenesis in the chicken chorioallantoic 
membrane (CAM) assay. Similar results were obtained with another RGD-disintegrin, 
rhodostomin, from Agkistrodon rhodostoma venom, which inhibits endothelial cell migration, 
invasion and tube formation induced by bFGF in MatrigelTM both in vitro and in vivo [47]. 
Rhodostomin effects were inhibited by anti-αvβ3 but not by anti-αvβ5 antibodies, thus 
supporting the hypothesis that the effects of RGD-disintegrins are mediated by blockade of 
the vitronectin receptor.  
Proteins Snake Integrins Effects References 
Triflavin Trimeresurus 
flavoviridis 
α5β1,αvβ3,
α3β1 
Inhibits adhesion of tumor 
cells to matrix proteins, cell 
migration and angiogenesis 
in vitro and in vivo 
[46] 
Rhodostomin Agikistrodon 
rhodostoma 
αvβ3,αvβ5 Inhibits cell migration, 
invasion of endothelial cells; 
inhibits angiogenesis in vivo 
and in vitro 
[47] 
Contortrostatin Agkistrodon 
contortrix 
contortrix 
αvβ3,α5β1,
αvβ5, 
αIIββ3 
Blocks adhesion, migration 
invasion of different type of 
tumor cells 
[48] 
Lebestatin Macrovipera 
lebetina 
α1β1 Inhibits migration and 
angiogenesis 
[56] 
Accurhagin-C Agkistrodon 
acutus 
αvβ3 Prevents migration and 
invasion of endothelial cells; 
anti-angiogenic activity in 
vitro and in vivo; elicites 
anoïkis 
[58] 
Eristostatin Eritocophis 
macmahoni 
α4β1,other 
integrin not 
yet 
determined
Inhibits cell motility; no 
effect on cell proliferation or 
angiogenesis 
[59,60] 
DisBa-01 Bothrops 
alternatus 
αvβ3 Anti-angiogenic and anti-
metastatic effect on 
melanoma cells 
[62] 
Leberagin-C Macrovipera 
lebetina 
αvβ3 Inhibits cell adhesion of 
melanoma tumor cells 
[114] 
Accutin Agkistrodon 
acutus 
αvβ3 Inhibits angiogenesis in vitro 
and in vivo; induces 
apoptosis 
[115] 
Table 2. Effects of disintegrins on cancerous cells 
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Contortrostatin, a disintegrin isolated from the venom of the southern copperhead snake, 
exhibits anti-cancer activity in a variety of tumor cells [48-50]. It does not display cytotoxic 
activity in vitro nor animals upon injection. Contortrostatin inhibits adhesion, migration, 
invasion, metastatic and angiogenesis of tumor and endothelial cells mediated by 
αvβ3,α5β1 and αvβ5 [48,50-54]. Recently, contortrostatin showed an additive inhibitory 
effect in combination with docetaxel on the growth of xenograft tumors derived from 
prostate cancer cells [55]. 
Lebestatin is an example of a non toxic KTS-disintegrin isolated from Macrovipera lebetina 
that inhibits migration and VEGF-induced in vivo angiogenesis [56]. The presence of a WGD 
motif in CC8, a heterodimeric disintegrin from Echis carinatus, increases its inhibitory effect 
on αvβ3 and α5β1 integrins [57]. 
There are few reports regarding the effects of ECD-disintegrins on endothelial cell 
migration. Acurhagin-C, dose-dependently blocked HUVEC migration toward a 
vitronectin-coated membrane. Furthermore, acurhagin-C elicited endothelial anoïkis via 
disruption of the αvβ3/FAK/PI3K survival cascade and subsequent initiation of the 
procaspase-3 apoptotic signaling pathway [58].  
Eristostatin, an RGD-disintegrin from Eristocophis macmahoni was tested on individual 
metastasis steps such as cell arrest, extravasation and migration [59]. Eristostatin treatment 
did not prevent tumor cell extravasation or migration [60]. However, it was shown later that 
eristostatin inhibited melanoma cell motility, an effect mediated by fibronectin-binding 
integrins [61]. Interestingly, this disintegrin, contrary to other RGD-disintegrins, did not 
inhibit angiogenesis, as stated before [61]. DisBa-01, a αvβ3 integrin-blocking RGD-
disintegrin, inhibits not only migration of endothelial cells in vivo [62] but also in vitro 
migratory ability of fibroblasts and two tumor cell lines. 
Since integrin receptors are also quite indiscriminate as they support cell adhesion to several 
substrates, it seems highly reasonable that the general RGD-disintegrin scaffold of the 
integrin-binding motif could be employed as a prototype for drug design for new anti-
metastatic therapies via blocking both tumor cell adhesion and tumor angiogenesis. 
2.3. The snake venom phospholipases 
Snake venom is one of the most abundant sources of secretory phospholipases A2 (PLA2), 
which are one of the potent molecules in snake venoms [63-65].  
PLA2 (EC 3.1.1.4)—are enzymes that catalyze the hydrolysis of sn-2-acyl bond of sn-3-
phospholipids, generating free fatty acids and lysophospholipids as products [66]. They are 
currently classified in 15 groups and many subgroups that include five distinct types of 
enzymes, namely secreted PLA2 (sPLA2), cytosolic PLA2 (cPLA2), Ca2+ independent PLA2s 
(iPLA2), platelet-activating factor acetyl-hydrolases (PAF-AH), lysosomal PLA2, and a 
recently identified adipose-specific PLA2 [65,67]. PLA2 are low molecular weight proteins 
with molecular masses ranging from 13-19 kDa that generally require Ca2+ for their activities 
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[69,70]. Snake venom sPLA2 are secreted enzymes belonging to only two groups that are 
based on their primary structure and disulfide bridge pattern [68,71,72]. Those of group I 
are similar to pancreatic sPLA2 present in mammals, were found in venom of Elapidae 
snakes, while group II PLA2s belong to the Viperidae and are similar to mammals 
nonpancreatic, inflammatory sPLA2s [73,74]. The group II can be subdivided mainly in two 
subgroups, depending on the residue at position 49 in the primary structure: Aspartic acid-
49 PLA2s are enzymatically active, while Lysine 49 present low or no enzymatic activity 
[75]. There are other subgroups, such as Asparagine-49, Serine-49, Glutamine-49 and 
Arginine -49 [76-83]. Studies have found that catalytic activity is reduced or even abolished 
when an Aspartic acid of native PLA2 is replaced by another amino acid [80,84]. 
Despite a high identity of their amino acid sequences, sPLA2 exhibit a wide variety of 
pharmacological properties such as anticoagulant, haemolytic, neurotoxic, myotoxic, 
oedema-inducing, hemorrhagic, cytolytic, cardiotoxic, muscarinic inhibitor and antiplatelet 
activities [63,85-92]. 
Recently, PLA2s have been shown to possess anti-tumor and anti-angiogenic properties 
(Table 3). CC-PLA2-1 and CC-PLA2-2 from Cerastes cerastes viper are non-toxic and acidic 
proteins. They have high inhibitory effects on platelet aggregation and coagulation. In 
addition, CC-PLA2-1 and CC-PLA2-2 inhibit the adhesion of the human fibrosarcoma 
(HT1080) and melanoma (IGR39) cells to fibrinogen and fibronectin. In the same direction, 
CC-PLA2-1 and CC-PLA2-2 potently reduces HT1080 cell migration to fibrinogen and 
fibronectin with nearly similar IC50 values [93]. This anti-adhesive effect was due to the 
inhibition of α5β1and αv-containing integrins [94]. A recent report demonstrated that Bth-
A-I, a non-toxic PLA2 isolated from Bothrops jararacussu venom display an anti-tumoral 
effect upon breast adenocarcinoma as well as upon human leukaemia T and Erlich ascetic 
tumor [95]. 
Proteins Snake Integrins Effects References 
CCPLA2-1; 
CCPLA2-2 
Cerastes 
cerastes 
α5β1,αv Inhibits migration and 
adhesion of fibrosarcoma 
and melanoma cells 
[93,94] 
Bth-A-I-
PLA2 
Bothrops 
jararacussu 
- 
Anti-tumor activity on 
adenocarcinoma and 
leukaemia cells 
[95] 
MVL-
PLA2 
Macrovipera 
lebetina 
α5β1,αv Inhibits adhesion and 
migration of human 
microvascular cells and 
inhibits angiogenesis in vivo 
and in vitro. 
[96] 
BP II Prothobotrops 
flavoviridis 
- Induces cell death in human 
leukaemia cells 
[97] 
Table 3. PLA2s targeting tumor cells 
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MVL-PLA2 is a snake venom phospholipase purified from Macrovipera lebetina venom 
that  inhibited adhesion and migration of human microvascular endothelial cells (HMEC-1) 
without being cytotoxic. Using MatrigelTM and chick chorioallantoic membrane assays, 
MVL-PLA2, as well as its catalytically inactivated form, significantly inhibited angiogenesis 
both in vitro and in vivo. Also, the actin cytoskeleton and the distribution of αvβ3 integrin, a 
critical regulator of angiogenesis and a major component of focal adhesions, were disturbed 
after MVL-PLA2 treatment. The enhancement of microtubule dynamics of HMEC-1 cells, in 
consequence of treatments by MVL-PLA2, may explain the alterations in the formation of 
focal adhesions, leading to inhibition of cell adhesion and migration [96].  
A cell death activity was discovered in Lysine 49-PLA2 called BPII. It induces caspase-
independent cell death in human leukaemia cells regardless of its depressed enzymatic 
activity [97]. 
2.4. The C-type lectins  
The C-type lectins are abundant components of snake venom with various function. 
Typically, these proteins bind calcium and sugar residues. However, the C-type lectin like 
proteins from snake venom (termed actually snaclec) does not contain the classic 
calcium/sugar binding loop and have evolved to bind a wide range of physiologically 
important proteins and receptors [98]. 
Snaclecs have a basic heterodimeric structure with two subunits, nearly always linked 
covalently, via a disulphide bond. The heterodimers are often further multimerized either 
non-covalently or covalently via additional disulphide bonds, to form larger structures [99]. 
The two subunits form a concave surface between them [100] thus constituting the main site 
of ligand binding [101,102]. The subunits have a high structural degree of homology 
between them and with other snaclecs [103]. Despite their highly conserved primary 
structure, the snaclecs are characterized by various biological activities. They were and are 
still considered as modulators of platelet aggregation by targeting vWF, GPIb-IX-V, GPVI 
and possibly other platelet receptors.  
Recently, novel activities of snaclecs were highlighted. They were described for their 
potential anti-tumor effect by blocking adhesion, migration, proliferation and invasion of 
different cancer cell lines (Table 4). Among these proteins, EMS16, a heterodimer isolated 
from the venom of Echis multisquamatus, inhibits the adhesion of HUVECs cells on ECM 
proteins and their migration by inhibiting the binding of integrin α2β1 to collagen [104].  
Lebecetin and lebectin, purified from Macrovipera lebetina venom, are the only snaclecs, until 
today, with an evident anti-tumor effect in addition to their anti-aggregation activity on 
platelets. Indeed, these two non cytotoxic proteins inhibit the adhesion of various cancer cell 
lines: melanoma (IGR39), adenocarcinoma (HT29-D4), fibrosarcoma (HT1080) and leukemia 
cells (K562) on different ECM proteins. They also inhibit the proliferation, migration and 
invasion of HT1080 cells [105,106]. Lebectin also displays anti-angiogenic activity at very 
low concentrations both in vitro and in vivo [107]. Thus, lebectin presents the best anti-
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angiogenic efficacy yet described for snake venom-derived peptides [108,109]. These 
observed effects are mediated by α5β1 and αv integrins [107].  
Extensive researches have been shown that cell adhesion activities in cancer disease are 
deregulated. According to this idea, it was also reported that lebectin inhibits these 
alterations by promoting N-cadherin/catenin complex reorganisation at cell-cell contacts, 
inducing a strengthening of intercellular adhesion [110].  
Another snaclec, BJcuL isolated from Bothrops jararacussa venom, was also described for its 
anti-tumor, but the receptor or integrin implicated has not been determined yet. This 
homodimeric protein inhibits proliferation of several cell lines of renal, pancreatic, prostate 
and melanoma origin, but no effect was observed on colon or breast cancer cells [111]. BJcuL 
also affects the viability of some tumor cell lines of different origins, but has no effect on the 
growth of K562 and T24 cells, suggesting that these cells do not express the receptor 
recognized by the lectin. BJcuL induces apoptosis in human gastric carcinoma cells 
accompanied by inhibition of cell adhesion and actin cytoskeleton disassembly [112].  
Proteins Snake Integrins Effects References 
Lebecetin, 
lebectin 
Macrovipera 
lebetina 
α5β1,αv Inhibits adhesion, migration and 
invasion of human tumor cells; 
inhibits angiogenesis 
[106] 
BJcuL Bothrops 
jararacussu 
 Inhibits tumor cell and endothelial 
cell growth; induces apoptosis of 
human gastric carcinoma cells; 
inhibits cell adhesion and actin 
cytoskeleton disassembly 
[111,112] 
EM16 Echis 
multisquamatus
α2β1 Inhibits adhesion and migration of 
HUVEC cells 
[104] 
Table 4. Snaclecs and their effects on tumor cells 
3. Potential application of snake venom compounds 
Venoms are a rich source of molecules endowed with diverse pharmacological effects. Most 
part of these molecules act via the adhesion molecules. The intervention of the scientists and 
the clinicians in the pharmaceutical development field would employ these molecules as 
therapeutic agents for several pathologies such as cancer, thrombosis, diabetes....  
Until now, no medicine was produced from a native molecule purified from venom. 
However, several peptidomimetics were designed by basing on the structure of these 
molecules. The benefits of these peptidomimetics compared to antibodies that can be used 
for the treatment of certain diseases are: a shorter half-life, reversible inhibition, easier to 
control a problem and very low immunogenicity. For example, the antihypertensive drug 
captopril, modelled from the venom of the Brazilian arrowhead viper (Bothrops jaracusa); the 
anticoagulant Integrilin (eptifibatide), a heptapeptide derived from a protein found in the 
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venom of the American southeastern pygmy rattlesnake (Sistrurus miliarius barbouri); 
Ancrod, a compound isolated from the venom of the Malaysian pit viper (Agkistrodon 
rhodostoma) for use in the treatment of heparin-induced thrombocytopenia and stroke and 
alfimeprase, a novel fibrinolytic metalloproteinase for thrombolysis derived from southern 
copperhead snake (Agkistrodon contortrix contortrix) venom (Table 5). Two venom proteins 
from the Australian brown snake, Pseudonaja textilis, are currently in development as human 
therapeutics (QRxPharma). The first is a single agent procoagulant that is a homolog of 
mammalian Factor Xa prothrombin activator, whereas the other is a plasmin inhibitor, 
named Textilinin-1, with antihemorrhagic properties.  
Name Snake Target and 
function/treatment 
Clinical stage 
Capoten ® 
(Captropil) Bothrops jaracusa
Angiotensin converted 
enzyme (ACE) inhibitor/ 
high blood pressure 
Granted FDA approval 
Integrilin ® 
(Eptifibatide) 
Sisturus miliarus 
barbouri 
Platelet aggregation 
inhibitor/acute coronary 
syndrome 
Granted FDA approval 
Aggrastat ® 
(tirofiban) 
Echis carinatus 
GPIIb-IIIa inhibitor/ 
myocardial infarct, 
refractory ischemia 
Approved for use with 
heparin and aspirin for 
the treatment of acute 
coronary syndrome 
Exanta 
Cobra 
Thrombin inhibitor/ 
arterial fibrillation and 
blood 
Seeking FDA approval 
Alfimeprase 
(Agkistrodon 
contortrix 
contortrix) 
Thrombolytic/ Acute 
ischemic stroke, acute 
peripheral arterial 
occlusion 
Phase III 
Ancrod ® 
(viprinex) 
Agkistrodon 
rhodostoma 
Fibrinogen inhibitor/ stroke Phase III 
hemocoagulase Bothrops atrox 
Thrombin-like effect and 
thromboplastin activity/ 
prevention and treatment 
of haemorrhage 
Phase III 
Protac/ Protein C 
activator 
Agkistrodon 
contortrix 
contortrix 
Protein C activator/clinical 
diagnosis of haemostatic 
disorder 
Granted FDA approval 
Reptilase 
Bothrops jaraca 
Diagnosis of blood 
coagulation disorder 
Granted FDA approval 
Ecarin 
Echis carinatus 
Prothrombin activator/ 
diagnostic 
Granted FDA approval 
Table 5. Drugs and clinical diagnostic kits from snake venom 
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Actually, most of the current anticancer therapies (radiotherapy, chemotherapy) are not 
specific and are targeting at both tumor cells and healthy cells. However, in recent years, 
new treatments tend to focus on the tumor microenvironment and particularly on the 
inhibition of tumor angiogenesis. These treatments are based on several active and non toxic 
proteins from snake venom, as for example contortrostatin from Agkistrodon contortrix 
contortrix and eristostatin from Eristocophis macmahoo. Although all these molecules are still 
currently in clinical trials, they could in the future open new ways of healing and could be 
used as drugs. 
4. Conclusions 
From the initial discovery of captopril, the first oral ACE inhibitor, to the recent application 
of disintegrins for the potential treatment of cancer, the various components of snake 
venoms have never failed to reveal amazing new properties. While the original native snake 
venom compounds are usually unsuitable as therapeutics, interventions by medicinal 
chemists as well as scientists and clinicians in pharmaceutical R&D have made it possible to 
use the snake venom proteins as potential drugs for multiple disorders or scaffolds for drug 
design.  
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